University of Florida Cancer and Genetics Research Complex

APSHO Welcomes Florida Cancer Specialists & Research Institute's Advanced Practitioners as APSHO Institutional Members

Retrieved on: 
Monday, October 30, 2023
Science, Hematology, Physician, University of Florida Cancer and Genetics Research Complex, Health, Journal, National Institute of Nursing Research, Cancer, Nurse practitioner, FCS, FNP, Patient, MSN, Evidence-based practice, Nursing

NEWTOWN, Pa., Oct. 30, 2023 /PRNewswire-PRWeb/ -- The Advanced Practitioner Society for Hematology and Oncology (APSHO) welcomes over 250 advanced practitioners—nurse practitioners and physician assistants—from Florida Cancer Specialists & Research Institute, LLC (FCS) as Institutional Members.

Key Points: 
  • Nurse practitioners and physician assistants from Florida Cancer Specialists & Research Institute, LLC join APSHO, a national network of health-care professionals devoted to a collaborative approach to cancer care.
  • NEWTOWN, Pa., Oct. 30, 2023 /PRNewswire-PRWeb/ -- The Advanced Practitioner Society for Hematology and Oncology (APSHO) welcomes over 250 advanced practitioners—nurse practitioners and physician assistants—from Florida Cancer Specialists & Research Institute, LLC (FCS) as Institutional Members.
  • "We applaud FCS' commitment to both patients and the advanced practitioners who care for them by joining APSHO as an Institutional Member," commented Wendy Vogel, FNP, AOCNP®, FAPO, APSHO's Executive Director.
  • APSHO, now over 5,000 members strong, is the only society dedicated to an interdisciplinary team approach to cancer treatment.

Institute for Value-Based Medicine® from The American Journal of Managed Care® hosts ‘Genomics, Real-World Evidence, and Phase 1 Innovations in a Community Oncology Practice’ event in Tampa

Retrieved on: 
Thursday, July 27, 2023
Real-World Evidence, University of Florida Cancer and Genetics Research Complex, IVBM, Partnership, AOCNP, MSN, Nursing, The American Journal of Managed Care, AJMC, Research, EDT, American Journal, Physician, FCS, Genomics

The in-person event, Genomics, Real-World Evidence, and Phase 1 Innovations in a Community Oncology Practice, will be held in partnership with Florida Cancer Specialists & Research Institute at Hilton Downtown Tampa from 5-9 p.m. EDT.

Key Points: 
  • The in-person event, Genomics, Real-World Evidence, and Phase 1 Innovations in a Community Oncology Practice, will be held in partnership with Florida Cancer Specialists & Research Institute at Hilton Downtown Tampa from 5-9 p.m. EDT.
  • “We are excited to partner with Florida Cancer Specialists & Research Institute (FCS) for this transformative event,” said Gil Hernandez, vice president of AJMC.
  • “Together, we will leverage the power of real-world evidence and discuss strategies to provide personalized care within community oncology practices.
  • With genomics, real-world evidence, and phase 1 innovations at the forefront, attendees will delve into the latest advancements and transformative breakthroughs in oncology.

Tampa General Hospital Opens Infusion Center at the TGH Cancer Institute's State-of-the-Art Satellite Location

Retrieved on: 
Wednesday, July 19, 2023
Proton, Tampa General Hospital, Travel, Accreditation, Drink, Ear, Indiana University Health Proton Therapy Center, Prescription, Nose, Hospital, Patient, ACS, Practitioner, American College, Health, News, Tissue, Bone marrow, Breast, HDR, Otorhinolaryngology, Liver, Skin, FCS, Cancer Institute, Radionuclide, COC, Cell, Radiopharmaceutical, Immunotherapy, Memorial Sloan Kettering Cancer Center, Research, University of Florida Cancer and Genetics Research Complex, Radiation, USF Health Byrd Alzheimer's Institute, Newsweek, Commission, Pharmacy, Radiation therapy, U.S. News & World Report, Physician, TGH, Proton therapy, Haematopoietic system, Throat, Nursing, Pharmaceutical industry, Medical imaging, Cancer, Oncology

TAMPA, Fla. , July 19, 2023 /PRNewswire/ -- In an endeavor to expand cancer care for the rapidly growing communities of south Hillsborough County, Tampa General Hospital (TGH) opened a state-of-the-art, 26-bay Infusion Center in the TGH Cancer Institute's Brandon location. A ribbon-cutting ceremony was held on July 19. Additionally, a Radiation Oncology Center will open at the Brandon location, 10740 Palm River Road, this fall.

Key Points: 
  • TAMPA, Fla. , July 19, 2023 /PRNewswire/ -- In an endeavor to expand cancer care for the rapidly growing communities of south Hillsborough County, Tampa General Hospital (TGH) opened a state-of-the-art, 26-bay Infusion Center in the TGH Cancer Institute's Brandon location.
  • "Our new TGH Cancer Institute location allows us to expand our reach and provide greater access to our community."
  • The TGH Cancer Institute satellite location in Brandon is part of Tampa General's $550 million master facility plan, the largest in the hospital's almost 100-year history.
  • The addition to the TGH Cancer Institute's Infusion Center will offer seven more chemotherapy areas for the treatment of cancer.

Tampa General Hospital Named One of America's Top Cancer Hospitals by Newsweek

Retrieved on: 
Wednesday, June 28, 2023
Proton, Online, News, Cyberknife, Medicine, Partnership, Accreditation, Cancer Institute, Education, COC, Proton therapy, Multiple myeloma, Hospital, Commission, Radiation, Quality of life, Research, HDR, BMT, University of Florida Cancer and Genetics Research Complex, Radiopharmaceutical, Radiation therapy, Patient, Tampa General Hospital, Reno CyberKnife, U.S. News & World Report, ACS, Lymphoma, TGH, Cell, Brachytherapy, Statista, Health, American College, Dentistry, Nursing, Pharmaceutical industry, Oncology, Newsweek, Tampa Bay, Cancer

TAMPA, Fla., June 28, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) is in the top 3% of cancer hospitals in the United States, according to Newsweek and Statista. Listed in the news magazine's new America's Best Cancer Hospitals 2023 rankings, Tampa General is also ranked in the top 10 Florida cancer facilities that appear on Newsweek's list.

Key Points: 
  • Tampa General Hospital Cancer Institute is ranked among the best cancer hospitals nationally.
  • TAMPA, Fla., June 28, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) is in the top 3% of cancer hospitals in the United States, according to Newsweek and Statista.
  • Listed in the news magazine's new America's Best Cancer Hospitals 2023 rankings, Tampa General is also ranked in the top 10 Florida cancer facilities that appear on Newsweek's list.
  • "This recognition is a testament to the incredible oncology team that leads the TGH Cancer Institute to deliver world-class, cutting-edge and compassionate cancer care," said John Couris, president and CEO of Tampa General.

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023
University of Florida Cancer and Genetics Research Complex, Malignancy, Therapy, Neoplasm, Breast, Cancer, Woman, Endometrial cancer, MBA, Central Time, Incidence, MICB, MICA, Patient, Cervical cancer, Memorial Sloan Kettering Cancer Center, Immune system, Escape Room, Research institute, Uterine cancer, MPH, Pembrolizumab, NKG2D, Safety, Pharmaceutical industry, MD

CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced first monotherapy clinical data from its Phase 1 study of CLN-619 in patients with advanced solid tumors. Findings from the clinical trial will be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting as a poster presentation during the “Developmental Therapeutics—Immunotherapy” session (poster # 2532) on June 3, 2023 from 8:00 AM-11:00 AM Central Time. CLN-619 is being studied in an ongoing Phase 1 clinical trial both as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.

Key Points: 
  • "We are encouraged by the first clinical data for CLN-619 monotherapy, which demonstrates broad potential across a range of tumor types.
  • “Notably, clinical activity was observed in multiple gynecologic cancer types of high unmet need.
  • Based on these initial efficacy observations, we will initiate expansion cohorts in endometrial and cervical cancer and look to expand in additional tumor-specific cohorts as the data matures.
  • Consistent with prespecified criteria and based on initial safety and efficacy observations, Cullinan will initiate monotherapy expansion cohorts in endometrial cancer and cervical cancer.

Nationwide Drug Shortage Calls for Immediate Reform on Pricing Regulation for Generic Drugs

Retrieved on: 
Monday, May 15, 2023
University of Florida Cancer and Genetics Research Complex, ASP, Breast, Carboplatin, Lung, Government, Pharmacist, Patient, Physician, Oncology, Cisplatin, Health, FCS, Property management, Nursing, Medical device, Pharmaceutical industry, MD

FORT MYERS, Fla., May 15, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is demanding reform in the pricing regulation of generic drugs, an issue that has deeply affected the oncology community for years but has worsened in recent months. Inadequacies in regulating average selling prices (ASP) for regimens crucial to patient care are directly affecting manufacturers' ability to maintain operations and productivity for critical generic drugs.

Key Points: 
  • Inadequacies in regulating average selling prices (ASP) for regimens crucial to patient care are directly affecting manufacturers' ability to maintain operations and productivity for critical generic drugs.
  • Oncology leaders from Florida Cancer Specialists & Research Institute call for pricing reform of generic cancer drugs.
  • The ask is for all involved or concerned to bring this issue to light with their state legislators and demand pricing regulation that will ensure ample supplies.
  • We must take action now to instill regulatory pricing that will enable consistent and reliable production of these critical drugs."

CIRCULOGENE's liquid biopsy for PD-L1 status features in research presented at the recent AACR annual meeting

Retrieved on: 
Friday, May 12, 2023
University of Florida Cancer and Genetics Research Complex, DNA, AACR, Wake Forest School of Medicine, ICI, Hematology, Liquid biopsy, Cancer, Toxicity, Research, Biomarker, RNA, Immunotherapy, Associate, Messenger, Plasma, American Association for Cancer Research, Patient, Immune system, Wake Forest University School of Divinity, CFRNA, Immunohistochemistry, Poster, Neoplasm, Oncology, Liquid, PD-L1, Breast cancer, Pharmaceutical industry, Medical imaging, Medicine

BIRMINGHAM, Ala. and PENSACOLA, Fla., May 12, 2023 /PRNewswire-PRWeb/ -- CIRCULOGENE is an innovative diagnostic company transforming precision medicine through the rapid delivery of actionable results. New research presented by Dr. Lowell Hart at the April 14-19 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida relied upon use of CIRCULOGENE's technology to identify biomarkers which indicate the efficacy of immune checkpoint inhibitors (ICI) therapy.

Key Points: 
  • New research presented by Dr. Lowell Hart at the April 14-19 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida relied upon use of CIRCULOGENE's technology to identify biomarkers which indicate the efficacy of immune checkpoint inhibitors (ICI) therapy.
  • The use of liquid biopsy could improve patient selection for ICI therapy and help clinicians to avoid unnecessary treatment-related toxicity in patients.
  • Liquid biopsies offer a less invasive approach to sampling tumor biology and a more accurate way to assess potential therapeutic response.
  • "And it's exciting to help patients benefit from immune checkpoint inhibitors who previously might not have had the opportunity."

Targeted Therapy Developed in FCS Clinical Trials Transforming Cancer Treatment For Adult Patients with Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
Friday, April 28, 2023
Lymphoma, University of Florida Cancer and Genetics Research Complex, Abstract, Polatuzumab vedotin, Hematology, DLBCL, Non-Hodgkin lymphoma, FACP, Bone marrow, Cancer, Quality of life, Exposition, Hope, MD, Patient, Lymph, Clinical research, Drug development, FDA, Society, FCS, Safety, Pharmaceutical industry, Medical device

FORT MYERS, Fla., April 28, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) today released a case study outlining the evolution of a newly FDA-approved first-line therapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The treatment regimen combines use of Polatuzumab Vedotin (POLIVY®), a type of anti-body drug conjugate that is significantly improving outcomes in patients with this aggressive form of lymphoma. FCS actively participated in the phase 1, first in-human monotherapy trial for polatuzumab vedotin, as well as the pivotal phase 3 Polarix study which led to its FDA approval as first-line treatment.

Key Points: 
  • The treatment regimen combines use of Polatuzumab Vedotin (POLIVY®), a type of anti-body drug conjugate that is significantly improving outcomes in patients with this aggressive form of lymphoma.
  • Florida Cancer Specialists & Research Institute clinical trials contribute to FDA approval of Polatuzumab Vedotin.
  • According to Gustavo Fonseca, MD, FACP , FCS Director of Clinical Research, patients in the Phase 3 study achieved rapid and sustained improvements.
  • FCS offers more than 300 clinical trials at three Phase 1 Drug Development Units and 37 clinic locations across Florida.

ASCO Guideline Update for Anxiety and Depression Released

Retrieved on: 
Thursday, April 27, 2023
University of Florida Cancer and Genetics Research Complex, Volunteering, Depression, Education, Quality, CBT, MS, Science, Wastewater treatment, ASCO, Outline, American Society of Clinical Oncology, Patient, Standard of care, Quality of life, Clinical, Health, MBSR, Survivor, Mental health, Society, FCS, Nursing, Anxiety, Adult, Cancer, MD

FORT MYERS, Fla., April 27, 2023 /PRNewswire/ -- A panel of multidisciplinary experts have reviewed previous American Society of Clinical Oncology (ASCO) guidelines for treating anxiety and depression in adult cancer survivors. The Practice Guidelines Implementation Network (PGIN) committee, which includes Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Barry Berman, MD, MS, released updates to the pre-existing guidelines last revised in 2014 in the abstract: "Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update."

Key Points: 
  • Florida Cancer Specialists & Research Institute Medical Oncologist Barry Berman, MD, MS, Serves on ASCO Anxiety & Depression Update Expert Panel
    FORT MYERS, Fla., April 27, 2023 /PRNewswire/ -- A panel of multidisciplinary experts have reviewed previous American Society of Clinical Oncology (ASCO) guidelines for treating anxiety and depression in adult cancer survivors.
  • The Practice Guidelines Implementation Network (PGIN) committee, which includes Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Barry Berman, MD, MS , released updates to the pre-existing guidelines last revised in 2014 in the abstract: "Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update."
  • The panel also draws attention to statistics supporting how depression and anxiety in cancer patients tend to be overlooked and therefore untreated as they are considered a normal reaction to a cancer diagnosis.
  • The guidelines then outline options for treating depression and anxiety as separate issues, as well as offering guidance when both are experienced.

Three Leading Cancer Centers Awarded Medically Integrated Pharmacy Accreditation

Retrieved on: 
Thursday, March 23, 2023
University of Florida Cancer and Genetics Research Complex, Pharmacy, Doctor of Pharmacy, Accreditation, COE, Hematology, Quality, European Hematology Association, Patient, ACHC, URAC, Nursing, Rx

CAZENOVIA, N.Y., March 23, 2023 /PRNewswire/ -- Three leading medically integrated oncology practices were awarded NCODA's Center of Excellence Medically Integrated Pharmacy Accreditation at the NCODA International Spring Forum that took place on March 15 – 17, 2023 in Indianapolis, IN.

Key Points: 
  • CAZENOVIA, N.Y., March 23, 2023 /PRNewswire/ -- Three leading medically integrated oncology practices were awarded NCODA's Center of Excellence Medically Integrated Pharmacy Accreditation at the NCODA International Spring Forum that took place on March 15 – 17, 2023 in Indianapolis, IN.
  • The only accreditation program designed specifically for medically integrated practices.
  • This three-year accreditation, based on compliance with the ASCO/NCODA Patient-Centered Standards for Medically Integrated Dispensing is the only accreditation program designed specifically for medically integrated practices.
  • These new offerings allow medically integrated pharmacies servicing multiple disease states to benefit from a patient-centered accreditation program without the presence of administrative burdens.